Live Chat

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren. 76,3% der Privatanlegerkonten verlieren Geld, wenn sie mit diesem Anbieter CFDs handeln. Sie sollten überlegen, ob Sie wirklich verstehen, wie CFDs funktionieren, und ob Sie es sich leisten können, das hohe Risiko von finanziellen Verlusten einzugehen.

Close

BioNTech Live-Chart

Einsichten

Weekly Search
Weekly
Daily
date Schließen change Veränderung in % Eröffnen Hoch Niedrig

Markets.com news

French election results to drive European markets
markets.com Support Team 2024 Jul 04, 21:00

Wochenausblick: Französische Wahlergebnisse entscheidend für europäische Märkte

Forex Indizes
Macron calls snap election, riles markets
markets.com Support Team 2024 Jun 29, 21:00

Wochenausblick: Frankreich als Auslöser einer Euro-Krise?

CPI
Businessman pointing hologram online banking icon.
markets.com Support Team 2024 Jun 20, 16:00

Wochenausblick: Jede Menge Daten und Inflationseinblicke

Forex Indizes
RBA, SNB, Bank of England rate decisions due next week
markets.com Support Team 2024 Jun 13, 21:00

Wochenausblick: RBA, Bank of England im Stick-or-Twist-Modus

Forex Indizes

Info

Spread

0.9949

Spread (%)

0.8754 %

Hebel

1:5

Übernacht-Zinsen (Kauf)

-0.0597 %

Übernacht-Zinsen (Verkauf)

-0.0292 %

Währung

USD

Handelszeiten

Markets closed

Dienstag

14:31 - 20:59

Montag

14:31-20:59

Mittwoch

14:31-20:59

Donnerstag

14:31-20:59

Freitag

14:31-20:59

Gewinn- und Verlustrechnung

Eröffnen

---

Vorher geschlossen

---

52-Wochen-Hoch/Tief

--- – ---

Marktkapitalisierung

27212888064

Ausstehende Aktien

239740000

Quartalsdatum (Nächstes)

0000-00-00

instr__dividend_date

2022-06-17

instr__ex_dividend_date

2022-06-02

instr__forward_annual_dividend_rate

0

instr__forward_annual_dividend_yield

0

EPS

-2.01

Ausstehende Aktien

BioNTech BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Erfahren Sie mehr über dieses Instrument

Basiswert
Verkaufen
Kaufen
Veränderung in %
Ähnliche Instrumente
Trustpilot
Live Chat